Search

Author/Creator Deconinck, E.

2. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. (5th January 2018)

Authors:
Craddock, C.; Versluis, J.; Labopin, M.; Socie, G.; Huynh, A.; Deconinck, E.; Volin, L.; Milpied, N.; Bourhis, J. H.; Rambaldi, A.; Chevallier, P.; Blaise, D.; Manz, M.; Vellenga, E.; Vekemans, M‐C.; Maertens, J.; Passweg, J.; Vyas, P.; Schmid, C.; Löwenberg, B.
Journal:
Journal of internal medicine
Issue:
Volume 283:Number 4(2018)
Page Start:
371
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN. (23rd June 2022)

Authors:
Pemmaraju, N.; Martinelli, G.; Todisco, E.; Tarella, C.; Montesinos, P.; Lane, A. A.; Erba, H. P.; Sweet, K. L.; Walter, R. B.; Deconinck, E.; Wang, E. S.; Aribi, A.; Ulrikson, M. L.; Levy, M. Y.; Lebon, D.; Marconi, G.; DeAngelo, D. J.; Rizzieri, D.; Konopleva, M.; Sloss, C. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1708
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017)

Authors:
Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; Contentin, N.; Yakoub‐Agha, I.; Cornillon, J.; Francois, S.; Turlure, P.; Charbonnier, A.; Rohrlich, P.; N'Guyen, S.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗